Charles River LaboratoriesCRL
CRL
$187.96
1.69%
Market Cap: $9.68B
0
Funds holding %
of 6,686 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
11% more repeat investments, than reductions
Existing positions increased: 258 | Existing positions reduced: 232
2% less funds holding
Funds holding: 666 [Q1] → 653 (-13) [Q2]
9.06% less ownership
Funds ownership: 110.81% [Q1] → 101.75% (-9.06%) [Q2]
15% less call options, than puts
Call options by funds: $54.2M | Put options by funds: $63.4M
15% less first-time investments, than exits
New positions opened: 75 | Existing positions closed: 88
24% less capital invested
Capital invested by funds: $14.2B [Q1] → $10.8B (-$3.33B) [Q2]
47% less funds holding in top 10
Funds holding in top 10: 15 [Q1] → 8 (-7) [Q2]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$191
2%
upside
Avg. target
$221
18%
upside
High target
$250
33%
upside
9 analyst ratings
4 positive
44%
5 neutral
56%
0 negative
0%
TD Cowen Charles Rhyee 29% 1-year accuracy 2 / 7 met price target | 8%upside $203 | Hold Maintained | 12 Aug 2024 |
Barclays Luke Sergott 60% 1-year accuracy 28 / 47 met price target | 12%upside $210 | Equal-Weight Maintained | 8 Aug 2024 |
UBS Dan Brennan 61% 1-year accuracy 17 / 28 met price target | 28%upside $240 | Buy Maintained | 8 Aug 2024 |
Evercore ISI Group Ross Muken 25% 1-year accuracy 1 / 4 met price target | 20%upside $225 | Outperform Maintained | 8 Aug 2024 |
Goldman Sachs Matthew Sykes 70% 1-year accuracy 37 / 53 met price target | 33%upside $250 | Buy Maintained | 8 Aug 2024 |
Financial journalist opinion
Based on 8 articles about CRL published over the past 30 days